Abstract
HIV-1 RNA level and darunavir concentration in the genital tract were measured in 45 men receiving darunavir-ritonavir mono- or tritherapy. At week 48, a low frequency (3/45) of HIV-1 RNA shedding was observed in patients (1 on monotherapy and 2 on triple therapy), although they had undetectable HIV-1 RNA in plasma. The median darunavir seminal plasma concentration was close to the blood plasma free fraction, demonstrating a good penetration of darunavir into the male genital tract.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Darunavir
-
Drug Administration Schedule
-
HIV Infections / blood
-
HIV Infections / drug therapy
-
HIV Infections / metabolism
-
HIV-1 / drug effects
-
HIV-1 / pathogenicity
-
Humans
-
Male
-
Plasma / chemistry
-
RNA, Viral / genetics
-
Reverse Transcriptase Inhibitors / blood
-
Reverse Transcriptase Inhibitors / metabolism
-
Reverse Transcriptase Inhibitors / therapeutic use*
-
Ritonavir / blood
-
Ritonavir / metabolism
-
Ritonavir / therapeutic use*
-
Semen / chemistry
-
Sulfonamides / blood
-
Sulfonamides / metabolism
-
Sulfonamides / therapeutic use*
Substances
-
RNA, Viral
-
Reverse Transcriptase Inhibitors
-
Sulfonamides
-
Ritonavir
-
Darunavir